...
首页> 外文期刊>HPB: the official journal of the International Hepato Pancreato Biliary Association >Determination of factors predictive of outcome for patients undergoing a pancreaticoduodenectomy of pancreatic head ductal adenocarcinomas
【24h】

Determination of factors predictive of outcome for patients undergoing a pancreaticoduodenectomy of pancreatic head ductal adenocarcinomas

机译:确定胰头十二指肠癌胰头十二指肠切除术患者预后的因素

获取原文
获取原文并翻译 | 示例

摘要

Introduction: A pancreaticoduodenectomy is the reference treatment for a resectable pancreatic head ductal adenocarcinoma. The probability of 5-year survival in patients undergoing such treatment is 5-25% and is associated with relatively high peri-operative morbidity and mortality. The objective of the present study was to evaluate risk factors predictive of outcome for patients undergoing a pancreaticoduodenectomy for a pancreatic adenocarcinoma. Methods: This retrospective analysis incorporated data from the Vancouver General Hospital and the British Columbia Cancer Agency (BCCA) from 1999-2007. Results: The 5-year survival of 100 patients was 12% with a median survival of 16.5 months. Ninety-day mortality was 7%. Predictors of 90-day mortality included age ≥ 80 years (P < 0.001) and an American Society of Anesthesiologists (ASA) score = 3 (P= 0.012) by univariate analysis and age ≥80 years (P < 0.001) by multivariate analysis. The identifiable predictive factor for poor 5-year survival was an ASA score = 3 (P= 0.043) whereas a Dindo-Clavien surgical complication grade ≥ 3 was associated with a worse outcome (P= 0.013). Referral to the BCCA was associated with a favourable 5-year survival (P= 0.001). Conclusions: The present study identifies risk factors for patient selection to enhance survival benefit in this patient population.
机译:简介:胰十二指肠切除术是可切除的胰头导管腺癌的参考治疗方法。接受此类治疗的患者5年生存的可能性为5-25%,并且与围手术期相对较高的发病率和死亡率相关。本研究的目的是评估接受胰腺十二指肠切除术治疗胰腺腺癌患者预后的危险因素。方法:这项回顾性分析纳入了温哥华总医院和不列颠哥伦比亚癌症局(BCCA)1999-2007年的数据。结果:100名患者的5年生存率为12%,中位生存期为16.5个月。九十天的死亡率为7%。 90天死亡率的预测因素包括年龄≥80岁(P <0.001)和通过单因素分析得出的美国麻醉医师协会(ASA)得分= 3(P = 0.012)和通过多元分析得出的≥80岁的年龄(P <0.001)。不良5年生存率的可识别预测因素是ASA评分= 3(P = 0.043),而Dindo-Clavien手术并发症≥3级则预后较差(P = 0.013)。转诊至BCCA与5年生存期有利(P = 0.001)。结论:本研究确定了患者选择的风险因素,以提高该患者群体的生存获益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号